Here, we present a protocol for establishing an okadaic acid-induced Alzheimer's disease cellular model in SH-SY5Y cells and evaluating the neuroprotective effects of gastrodin through oxidative stress and AKT/GSK-3β pathway analysis.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Research Article
* These authors contributed equally
Here, we present a protocol for establishing an okadaic acid-induced Alzheimer's disease cellular model in SH-SY5Y cells and evaluating the neuroprotective effects of gastrodin through oxidative stress and AKT/GSK-3β pathway analysis.
Alzheimer's disease (AD) is a common neurodegenerative disease for which there are currently limited effective drugs. As the principal bioactive component derived from Gastrodia elata, Gastrodin (GAS) has shown clear therapeutic potential for treating AD; however, the molecular mechanism of its action remains to be elucidated. In this study, we aim to investigate the mechanism of the effect of GAS on AD model cells. Network pharmacology is employed to analyze the targets and signaling pathways affected by GAS in AD. An AD cell model is constructed by inducing human neuroblastoma SH-SY5Y cells with Okadaic acid (OA). Cell viability was assessed using the CCK-8 assay, while the levels of SOD, MDA, and T-AOC were measured. Apoptosis rate was determined through Annexin V-FITC/PI double staining, and expression of apoptosis-related factors, as well as AKT, GSK-3β, p-Tau (Ser396), and p-Tau (Thr181), was analyzed using RT-qPCR and Western blotting techniques. Network pharmacology analysis suggests that GAS has the potential to regulate cellular apoptosis and associated signaling pathways, including PI3K/AKT. Our experiments demonstrate that GAS can inhibit MDA levels, increase T-AOC and SOD in the AD model cells, and reduce cell apoptosis. Western blotting results indicate that GAS mitigates OA's inhibitory effects on p-AKT (Ser473) and p-GSK-3β (Ser9) expression. Additionally, it attenuates the overexpression of p-Tau (Ser396) and p-Tau (Thr181), suppresses Bax expression, and enhances Bcl-2 expression. GAS demonstrates the ability to ameliorate oxidative stress injury induced by OA and mitigate apoptosis. GAS may suppress Tau hyperphosphorylation, which is associated with changes in the AKT/GSK-3β signaling pathway, thereby exerting potential neuroprotective effects.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory loss and cognitive impairment, representing the most prevalent form of dementia worldwide, accounting for approximately 60% to 80% of cases1. The underlying pathogenesis of AD remains complex and not yet fully elucidated2. Key pathological hallmarks observed in clinical AD cases include the accumulation of Senile Plaques (SP) and Neurofibrillary Tangles (NFTs) within the brain3,4. It is well recognized that the two core pathological events in AD are extracellula....
Access restricted. Please log in or start a trial to view this content.
All network pharmacology operations were conducted in accordance with the Guidelines for Network Pharmacology Evaluation Methods. All experimental procedures were performed in compliance with Zhejiang Sci-Tech University laboratory management regulations.
Network pharmacology
Prediction of potential targets of GAS: The canonical SMILES of GAS (PubChem CID: 1150) was retrieved from the PubChem database42. The SMILES structure was uploaded to the SwissTargetPrediction database (http://www.swisstargetprediction.ch/)43. The species parameter was set to Homo sapiens. Pre....
Access restricted. Please log in or start a trial to view this content.
GAS-related target screening for AD treatment
The identification of GAS's targets for treating AD involved database searches and software analysis. The Swiss Target Prediction database yielded 100 potential targets, while OMIM and GeneCards (with a Relevance score > 10) were queried for AD-related targets, resulting in a total of 2376 potential targets. Subsequently, employing the Venny 2.1 online platform enabled the identification of 52 potential therapeutic targets for GAS in AD (
Access restricted. Please log in or start a trial to view this content.
In recent years, there has been a global increase in the prevalence of AD. This condition is characterized by a chronic course, irreversible nature, disability, and elevated mortality rates, making it a significant challenge within the context of an aging global population. Despite its prominence, the etiology of AD is intricate, and its pathogenesis remains incompletely understood51.
Traditional Chinese medicine offers significant advantages in disease prevention and t.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This research was supported by the Open Fund of Zhejiang Sci-Tech University, Shaoxing Academy of Biomedicine (SXAB202007).
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 7500 Real-Time PCR System | APExBIO | S0080 | Used for detecting apoptotic cells |
| A450 enzyme labeling instrument | Proteintech | 50599-2-Ig | WB, dilution 1:1000 |
| Annexin V-FITC apoptosis detection kit | Proteintech | 60178-1-Ig | WB, dilution 1:1000 |
| Anti-Bax antibody | Proteintech | 10494-1-AP | WB, dilution 1:1000 |
| Anti-Bcl-2 antibody | Abcam | ab32057 | WB, dilution 1:1000 |
| Anti-GAPDH antibody | Proteintech | 28866-1-AP | WB, dilution 1:1000 |
| Anti-p-Tau (Ser396) antibody | Biofroxx | 1172 | Blocking buffer for WB |
| Anti-p-Tau (Thr181) antibody | Vazyme Biotech | A311-01/02 | Used for cell viability assay |
| Biofroxx skim milk powder | Solarbio Science & Technology | D8371 | Solvent for compounds |
| CCK-8 kit | Wisent Biotechnology | 319-105-CL | For cell culture |
| Dimethyl sulfoxide (DMSO) | APExBIO (USA) | K1231 | WB detection reagent |
| DMEM high-glucose medium | Aladdin Biochemical Technology | G111309 | Active compound |
| ECL chemiluminescent reagent | Promega | A6101 | For qPCR amplification |
| Flow cytometer | Solarbio Science & Technology | BC6410 | Lipid peroxidation assay |
| Gastrodin (GAS) powder, purity ≥98% | MedChemExpress | HY-N6785 | Inducer of tau hyperphosphorylation |
| Gel imaging system | Beyotime Biotechnology | C0221A | Wash the cells |
| GoTaq qPCR Master Mix | Proteintech | SA00001-1 | WB, dilution 1:5000 |
| MDA assay kit (malondialdehyde) | Proteintech | SA00001-2 | WB, dilution 1:5000 |
| Okadaic acid (OA) | ATCC | CRL-2266 | Cell |
| PBS | Beyotime Biotechnology | S0101M | For oxidative stress assay |
| Secondary antibody (Goat anti-mouse IgG, HRP-conjugated) | Solarbio Science & Technology | BC1315 | Antioxidant capacity detection |
| Secondary antibody (Goat anti-rabbit IgG, HRP-conjugated) | Beyotime Biotechnology | R0016 | RNA extraction |
| SH-SY5Y | Sigma-Aldrich | 9002-07-7 | Cell digestion |
| SOD assay kit (total superoxide dismutase) | Thermo Fisher Scientific | A45072 | Multifunctional microplate reader for absorbance detection |
| Total antioxidant capacity (T-AOC) kit | Becton, Dickinson and Company | 661310 | For multi-parameter single-cell analysis and cell sorting. |
| Trizol reagent | Thermo Fisher Scientific | 4351104 | gene expression analysis |
| Trypsin | Bio Rad | 1708195 | DNA/RNA/protein gel imaging |
Access restricted. Please log in or start a trial to view this content.